Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi

Highlights

• Butyrolactol A synergizes with caspofungin against cryptococci and Candida auris

• BLA restores echinocandin efficacy by targeting the Apt1-Cdc50 flippase complex

• Cryo-EM shows BLA traps the Apt1-Cdc50 phospholipid flippase in a dead-end state

• BLA blocks lipid transport, disrupts membrane homeostasis, and boosts drug uptake

Summary

Fungal infections cause millions of deaths annually and are challenging to treat due to limited therapeutic options and rising resistance. Cryptococci are intrinsically resistant to the latest generation of antifungals, echinocandins, while Candida auris, a notorious global threat, is also increasingly resistant. We performed a natural product screen to rescue caspofungin fungicidal activity against Cryptococcus neoformans H99 and identified butyrolactol A, which restores echinocandin efficacy against resistant fungal pathogens, including multidrug-resistant C. auris. Mode-of-action studies reveal that butyrolactol A inhibits the phospholipid flippase Apt1-Cdc50, blocking phospholipid transport. Cryo-electron microscopy analysis of the Apt1-butyrolactol A complex reveals that the flippase is trapped in a dead-end state. Apt1 inhibition disrupts membrane asymmetry, vesicular trafficking, and cytoskeletal organization, thereby enhancing echinocandin uptake and potency. This study identifies lipid flippases as promising antifungal targets and demonstrates the potential of revisiting natural products to expand the antifungal arsenal and combat resistance.

Read more at:

https://www.sciencedirect.com/science/article/abs/pii/S0092867425013716